BXCL501 + Matching Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Agitation
Conditions
Agitation, Dementia
Trial Timeline
Dec 14, 2022 → Sep 11, 2023
NCT ID
NCT05665088About BXCL501 + Matching Placebo
BXCL501 + Matching Placebo is a phase 3 stage product being developed by BioXcel Therapeutics for Agitation. The current trial status is terminated. This product is registered under clinical trial identifier NCT05665088. Target conditions include Agitation, Dementia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05665088 | Phase 3 | Terminated |
| NCT05658510 | Phase 3 | Completed |
| NCT05271552 | Phase 3 | Completed |
Competing Products
20 competing products in Agitation